Vanguard CPV-L
Active substance
ATC code
Species
Dogs
Indications
Active immunisation of dogs to prevent clinical signs including leucopenia and reduce viral shedding caused by canine parvovirus (type 2a), to prevent mortality and clinical signs including leucopenia and reduce viral shedding caused by canine parvovirus (types 2b and 2c), and to reduce clinical signs and infection due to Leptospira canicola and Leptospira icterohaemorrhagiae.
Onset of immunity occurs by approximately two weeks after the last dose of the Basic Vaccination Scheme. Onset of immunity for the canine parvovirus component (type 2b) occurs 7 days after a single dose when animals are vaccinated from 9 weeks of age.
The duration of immunity is at least 12 months.
Dose to be administered and administration route
Dosage and route of administration:
Shake well and immediately inject the entire contents of the vial (1 ml) subcutaneously. Do not use chemically sterilised syringes or needles, as these will interfere with the effectiveness of the vaccine.
Basic Vaccination Scheme:
Puppies younger than 10 weeks of age
Two doses of Vanguard CPV-L at least 14 days apart. The first dose can be given as young as 7 weeks of age. The second dose should not be given until at least 10 weeks of age.
Puppies 10 weeks of age and older
A single dose of Vanguard CPV-L, followed by a single dose of Vanguard Lepto-ci at least 14 days later
Re-vaccination Scheme:
A single dose of Vanguard CPV-L to be given annually thereafter
Adverse reactions
Vaccinated dogs may have a transient swelling 4-6 hours after vaccination which resolves after approximately 7 days.
If a systemic anaphylactic reaction occurs (eg vomiting), administer adrenaline or an equivalent.
